Delaying the oocyte maturation trigger by one day leads to a higher metaphase II oocyte yield in IVF/ICSI: a randomised controlled trial

Frank Vandekerckhove, Jan Gerris, Stijn Vansteelandt, An De Baerdemaeker, Kelly Tilleman, Petra De Sutter, Frank Vandekerckhove, Jan Gerris, Stijn Vansteelandt, An De Baerdemaeker, Kelly Tilleman, Petra De Sutter

Abstract

Background: The negative impact of rising progesterone levels on pregnancy rates is well known, but data on mature oocyte yield are conflicting. We examined whether delaying the oocyte maturation trigger in IVF/ICSI affected the number of mature oocytes and investigated the potential influence of serum progesterone levels in this process.

Methods: Between January 31, 2011, and December 31, 2011, 262 consecutive patients were monitored using ultrasound plus hormonal evaluation. Those with > =3 follicles with a mean diameter of > =18 mm were divided into 2 groups depending on their serum progesterone levels. In cases with a progesterone level < = 1 ng/ml, which was observed in 59 patients, 30-50% of their total number of follicles (only counting those larger than 10 mm) were at least 18 mm in diameter. These patients were randomised into 2 groups: in one group, final oocyte maturation was triggered the same day; for the other, maturation was triggered 24 hours later. Seventy-two patients with progesterone levels > 1 ng/ml were randomised in the same manner, irrespective of the percentage of larger follicles (> = 18 mm). The number of metaphase II oocytes was our primary outcome variable. Because some patients were included more than once, correction for duplicate patients was performed.

Results: In the study arm with low progesterone (<= 1 ng/ml), the mean number of metaphase II oocytes (+/-SD) was 10.29 (+/-6.35) in the group with delayed administration of the oocyte maturation trigger versus 7.64 (+/-3.26) in the control group. After adjusting for age, the mean difference was 2.41 (95% CI: 0.22-4.61; p = 0.031). In the study arm with elevated progesterone (>1 ng/ml), the mean numbers of metaphase II oocytes (+/-SD) were 11.81 (+/-9.91) and 12.03 (+/-7.09) for the delayed and control groups, respectively. After adjusting for PCOS (polycystic ovary syndrome) and female pathology, the mean difference was -0.44 (95% CI: -3.65-2.78; p = 0.79).

Conclusions: Delaying oocyte maturation in patients with low progesterone levels yields greater numbers of mature oocytes.

Trial registration: ClinicalTrials.gov NCT01980563.

Figures

Figure 1
Figure 1
CONSORT flow chart.
Figure 2
Figure 2
The distribution of follicle diameters in patients with normal serum progesterone (

Figure 3

The distribution of progesterone levels…

Figure 3

The distribution of progesterone levels in patients with elevated serum progesterone (>1…

Figure 3
The distribution of progesterone levels in patients with elevated serum progesterone (>1 ng/ml).
Figure 3
Figure 3
The distribution of progesterone levels in patients with elevated serum progesterone (>1 ng/ml).

References

    1. Ectors FJ, Vanderzwalmen P, VanHoeck J, Nijs M, Verhaegen G, Delvigne A, Schoysman R, Leroy F. Relationship of human follicular diameter with oocyte fertilization and development after in-vitro fertilization or intracytoplasmic sperm injection. Hum Reprod. 1997;12:2002–2005. doi: 10.1093/humrep/12.9.2002.
    1. Inaudi P, Germond M, Senn A, Degrandi P. Timing of Hcg administration in cycles stimulated for in-vitro fertilization - specific impact of heterogeneous follicle sizes and steroid concentrations in plasma and follicle fluid on decision procedures. Gynecol Endocrinol. 1995;9:201–208. doi: 10.3109/09513599509160447.
    1. Kwan I, Bhattacharya S, McNeil A, Van Rumste MME. Monitoring of stimulated cycles in assisted reproduction IVF and ICSI. Cochrane Database Syst Rev. 2008. [ ]
    1. Kyrou D, Kolibianakis EM, Fatemi HM, Tarlatzis BC, Tournaye H, Devroey P. Is earlier administration of human chorionic gonadotrophin (hCG) associated with the probability of pregnancy in cycles stimulated with recombinant follicle-stimulating hormone and gonadotrophin-releasing hormone (GnRH) antagonists? A prospective randomized trial. Fertil Steril. 2011;96:1112–1115. doi: 10.1016/j.fertnstert.2011.08.029.
    1. Garcia-Velasco JA, Isaza V, Vidal C, Landazabal A, Remohi J, Simon C, Pellicer A. Human ovarian steroid secretion in vivo: effects of GnRH agonist versus antagonist (cetrorelix) Hum Reprod. 2001;16:2533–2539. doi: 10.1093/humrep/16.12.2533.
    1. Bosch E, Labarta E, Crespo J, Simon C, Remohi J, Jenkins J, Pellicer A. Circulating progesterone levels and ongoing pregnancy rates in controlled ovarian stimulation cycles for in vitro fertilization: analysis of over 4000 cycles. Hum Reprod. 2010;25:2092–2100. doi: 10.1093/humrep/deq125.
    1. Dirckx K, Cabri P, Merien A, Galajdova L, Gerris J, Dhont M, De Sutter P. Does low-dose aspirin improve pregnancy rate in IVF/ICSI? A randomized double-blind placebo controlled trial. Hum Reprod. 2009;24:856–860.
    1. Zegers-Hochschild F, Adamson GD, De Mouzon J, Ishihara O, Mansour R, Nygren K, Sullivan E, van der Poel S. International Committee for Monitoring Assisted Reproductive T, World Health O: The International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) Revised Glossary on ART Terminology, 2009. Hum Reprod. 2009;24:2683–2687. doi: 10.1093/humrep/dep343.
    1. Kolibianakis EM, Bourgain C, Papanikolaou EG, Camus M, Tournaye H, Van Steirteghem AC, Devroey P. Prolongation of follicular phase by delaying hCG administration results in a higher incidence of endometrial advancement on the day of oocyte retrieval in GnRH antagonist cycles. Hum Reprod. 2005;20:2453–2456. doi: 10.1093/humrep/dei069.
    1. Venetis CA, Kolibianakis EM, Papanikolaou E, Bontis J, Devroey P, Tarlatzis BC. Is progesterone elevation on the day of human chorionic gonadotrophin administration associated with the probability of pregnancy in in vitro fertilization? A systematic review and meta-analysis. Hum Reprod Update. 2007;13:343–355. doi: 10.1093/humupd/dmm007.
    1. Venetis CA, Kolibianakis EM, Bosdou JK, Tarlatzis BC. Progesterone elevation and probability of pregnancy after IVF: a systematic review and meta-analysis of over 60 000 cycles. Hum Reprod Update. 2013;19:433–457. doi: 10.1093/humupd/dmt014.
    1. Cetinkaya ES, Berker B, Aytac R, Atabekoglu C, Sonmezer M, Ozmen B. The value of the progesterone-to-estradiol ratio on the day of hCG administration in predicting ongoing pregnancy and live birth rates in normoresponders undergoing GnRH antagonist cycles. Eur J Obstet Gynecol Reprod Biol. 2013;170:452–457. doi: 10.1016/j.ejogrb.2013.07.033.
    1. Kyrou D, Al-Azemi M, Papanikolaou EG, Donoso P, Tziomalos K, Devroey P, Fatemi HM. The relationship of premature progesterone rise with serum estradiol levels and number of follicles in GnRH antagonist/recombinant FSH-stimulated cycles. Eur J Obstet Gynecol Reprod Biol. 2012;162:165–168. doi: 10.1016/j.ejogrb.2012.02.025.
    1. Al-Azemi M, Kyrou D, Kolibianakis EM, Humaidan P, Van Vaerenbergh I, Devroey P, Fatemi HM. Elevated progesterone during ovarian stimulation for IVF. Reprod Biomed Online. 2012;24:381–388. doi: 10.1016/j.rbmo.2012.01.010.
    1. Silverberg KM, Martin M, Olive DL, Burns WN, Schenken RS. Elevated serum progesterone levels on the day of human chorionic-gonadotrophin administration in in-vitro fertilization cycles do not adversely affect embryo quality. Fertil Steril. 1994;61:508–513.
    1. Van Vaerenbergh I, Fatemi HM, Blockeel C, Van Lommel L, In't Veld P, Schuit F, Kolibianakis EM, Devroey P, Bourgain C. Progesterone rise on HCG day in GnRH antagonist/rFSH stimulated cycles affects endometrial gene expression. Reprod Biomed Online. 2011;22:263–271. doi: 10.1016/j.rbmo.2010.11.002.
    1. Mio Y, Sekijima A, Iwabe T, Onohara Y, Harada T, Terakawa N. Subtle rise in serum progesterone during the follicular phase as a predictor of the outcome of invitro fertilization. Fertil Steril. 1992;58:159–166.
    1. Bustillo M, Stern JJ, Coulam CB. Serum progesterone at the time of human chorionic gonadotrophin does not predict pregnancy in in-vitro fertilization and embryo transfer. Hum Reprod. 1995;10:2862–2867.
    1. Fatemi HM, Blockeel C, Devroey P. Ovarian stimulation: today and tomorrow. Curr Pharm Biotechnol. 2012;13:392–397. doi: 10.2174/138920112799362007.
    1. Murad NM. Ultrasound or ultrasound and hormonal determinations for in vitro fertilization monitoring. Int J Gynaecol Obstet. 1998;63:271–276. doi: 10.1016/S0020-7292(98)00111-8.
    1. De Sutter P, Dhont M. Poor response after hormonal stimulation for in vitro fertilization is not related to ovarian aging. Fertil Steril. 2003;79:1294–1298. doi: 10.1016/S0015-0282(03)00264-4.
    1. Elgindy EA. Progesterone level and progesterone/estradiol ratio on the day of hCG administration: detrimental cutoff levels and new treatment strategy. Fertil Steril. 2011;95:1639–1644. doi: 10.1016/j.fertnstert.2010.12.065.
    1. Golan A, Herman A, Soffer Y, Bukovsky I, Ronel R. Ultrasonic control without hormone determination for ovulation induction in in-vitro fertilization-embryo transfer with gonadotrophin-releasing-hormone analog and human menopausal gonadotrophin. Hum Reprod. 1994;9:1631–1633.
    1. Kovacs P, Kovats T, Bernard A, Zadori J, Szmatona G, Kaali SG. Comparison of serum and follicular fluid hormone levels with recombinant and urinary human chorionic gonadotrophin during in vitro fertilization. Fertil Steril. 2008;90:2133–2137. doi: 10.1016/j.fertnstert.2007.10.015.
    1. Lass A. Group UKToh: Monitoring of in vitro fertilization-embryo transfer cycles by ultrasound versus by ultrasound and hormonal levels: a prospective, multicenter, randomized study. Fertil Steril. 2003;80:80–85.
    1. Miller KF, Goldberg JM, Falcone T. Follicle size and implantation of embryos from in vitro fertilization. Obstet Gynecol. 1996;88:583–586. doi: 10.1016/0029-7844(96)00241-4.
    1. Mochtar MH, Custers IM, Koks CAM, Bernardus RE, Verhoeve HR, Mol BW, Van Wely M, van der Veen F. Timing oocyte collection in GnRH agonists down-regulated IVF and ICSI cycles: a randomized clinical trial. Hum Reprod. 2011;26:1091–1096. doi: 10.1093/humrep/der048.
    1. Tan SL, Balen A, El Hussein E, Mills C, Campbell S, Yovich J, Jacobs HS. A prospective randomized study of the optimum timing of human chorionic gonadotrophin administration after pituitary desensitization in in vitro fertilization. Fertil Steril. 1992;57:1259–1264.
    1. Hauzman EE, Bodri D, Guillen JJ, Vidal R, Coll O, Vernaeve V. Exploring different criteria by 2D or 3D ultrasound for triggering final oocyte maturation in an oocyte donation program: a randomized pilot study. Hum Reprod. 2011;26:I95–I96.
    1. Kolibianakis EM, Albano C, Camus M, Tournaye H, Van Steirteghem AC, Devroey P. Prolongation of the follicular phase in in vitro fertilization results in a lower ongoing pregnancy rate in cycles stimulated with recombinant follicle-stimulating hormone and gonadotrophin-releasing hormone antagonists. Fertil Steril. 2004;82:102–107.
    1. Kolibianakis EM, Papanikolaou EG, Tournaye H, Camus M, Van Steirteghem AC, Devroey P. Triggering final oocyte maturation using different doses of human chorionic gonadotrophin: a randomized pilot study in patients with polycystic ovary syndrome treated with gonadotrophin-releasing hormone antagonists and recombinant follicle-stimulating hormone. Fertil Steril. 2007;88:1382–1388. doi: 10.1016/j.fertnstert.2006.12.058.
    1. Tarlatzis BC, Fauser BC, Kolibianakis EM, Diedrich K, Devroey P. GnRH antagonists in ovarian stimulation for IVF. Hum Reprod Update. 2006;12:333–340. doi: 10.1093/humupd/dml001.
    1. Tremellen KP, Lane M. Avoidance of weekend oocyte retrievals during GnRH antagonist treatment by simple advancement or delay of hCG administration does not adversely affect IVF live birth outcomes. Hum Reprod. 2010;25:1219–1224. doi: 10.1093/humrep/deq059.
    1. Stanger JD, Yovich JL. Follicle recruitment determines IVF productivity rate via the number of embryos frozen and subsequent transfers. Reprod Biomed Online. 2013;27:286–296. doi: 10.1016/j.rbmo.2013.05.015.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe